Health and Healthcare
What This FDA Update Means for Equillium's COVID-19 Study
Published:
Equillium Inc. (NASDAQ: EQ) shares jumped on Friday after the company announced a key update from the U.S. Food and Administration (FDA) regarding its late-stage COVID-19 trial.
Specifically, the company received a letter from the FDA that it may begin its Phase 3 Equinox clinical trial evaluating itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome.
Equillium plans to start enrolling patients during the fourth quarter of 2020, and initial clinical data is expected mid-year 2021. The FDA has indicated that the trial, if it meets its primary and key secondary endpoints, may be sufficient to support regulatory filing of a Biologic License Application.
The Phase 3 Equinox trial will enroll a total of 800 patients at sites in the United States and abroad, with patients randomized on a one-to-one basis of receiving itolizumab or a placebo.
The primary endpoint of the trial is to evaluate the benefit of itolizumab on recovery in patients hospitalized with COVID-19. Key secondary endpoints include mortality benefit and other measures of clinical improvement.
In July, the Equillium announced that its partner Biocon reported a Phase 2 data from its clinical trial of itolizumab in India. Results demonstrated significantly reduced mortality over one month as compared to placebo in patients hospitalized with COVID-19.
Looking forward, Equillium and Biocon are working closely together on the further development of itolizumab in COVID-19 patients. The duo is also planning to scale up manufacturing to support access to treatment for the greatest possible number of patients worldwide.
Excluding Friday’s move, Equillium stock had outperformed the broad markets with a gain of about 78% year to date. In the past 52 weeks, the share price was up about 89%.
Equillium stock traded up about 12% on Friday, at $6.74 in a 52-week range of $2.20 to $27.05. The consensus price target is $18.75.
The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
